253 related articles for article (PubMed ID: 21455721)
21. Stage-specific action of matrix metalloproteinases influences progressive hereditary kidney disease.
Zeisberg M; Khurana M; Rao VH; Cosgrove D; Rougier JP; Werner MC; Shield CF; Werb Z; Kalluri R
PLoS Med; 2006 Apr; 3(4):e100. PubMed ID: 16509766
[TBL] [Abstract][Full Text] [Related]
22. Upregulated expression of integrin α1 in mesangial cells and integrin α3 and vimentin in podocytes of Col4a3-null (Alport) mice.
Steenhard BM; Vanacore R; Friedman D; Zelenchuk A; Stroganova L; Isom K; St John PL; Hudson BG; Abrahamson DR
PLoS One; 2012; 7(12):e50745. PubMed ID: 23236390
[TBL] [Abstract][Full Text] [Related]
23. Loss of the BMP antagonist USAG-1 ameliorates disease in a mouse model of the progressive hereditary kidney disease Alport syndrome.
Tanaka M; Asada M; Higashi AY; Nakamura J; Oguchi A; Tomita M; Yamada S; Asada N; Takase M; Okuda T; Kawachi H; Economides AN; Robertson E; Takahashi S; Sakurai T; Goldschmeding R; Muso E; Fukatsu A; Kita T; Yanagita M
J Clin Invest; 2010 Mar; 120(3):768-77. PubMed ID: 20197625
[TBL] [Abstract][Full Text] [Related]
24. [Molecular genetics of Alport syndrome].
Yamazaki H; Saito A; Nakagawa Y; Arakawa M
Nihon Rinsho; 1992 Dec; 50(12):3021-6. PubMed ID: 1491454
[TBL] [Abstract][Full Text] [Related]
25. Thin glomerular basement membrane disease: clinical significance of a morphological diagnosis--a collaborative study of the Italian Renal Immunopathology Group.
Frascà GM; Onetti-Muda A; Mari F; Longo I; Scala E; Pescucci C; Roccatello D; Alpa M; Coppo R; Li Volti G; Feriozzi S; Bergesio F; Schena FP; Renieri A;
Nephrol Dial Transplant; 2005 Mar; 20(3):545-51. PubMed ID: 15618242
[TBL] [Abstract][Full Text] [Related]
26. X-Linked and Autosomal Recessive Alport Syndrome: Pathogenic Variant Features and Further Genotype-Phenotype Correlations.
Savige J; Storey H; Il Cheong H; Gyung Kang H; Park E; Hilbert P; Persikov A; Torres-Fernandez C; Ars E; Torra R; Hertz JM; Thomassen M; Shagam L; Wang D; Wang Y; Flinter F; Nagel M
PLoS One; 2016; 11(9):e0161802. PubMed ID: 27627812
[TBL] [Abstract][Full Text] [Related]
27. Laminin-1 reexpression in Alport mouse glomerular basement membranes.
Abrahamson DR; Prettyman AC; Robert B; St John PL
Kidney Int; 2003 Mar; 63(3):826-34. PubMed ID: 12631063
[TBL] [Abstract][Full Text] [Related]
28. Effect of heterozygous pathogenic COL4A3 or COL4A4 variants on patients with X-linked Alport syndrome.
Zhang Y; Ding J; Zhang H; Yao Y; Xiao H; Wang S; Wang F
Mol Genet Genomic Med; 2019 May; 7(5):e647. PubMed ID: 30883042
[TBL] [Abstract][Full Text] [Related]
29. Alport Syndrome: Achieving Early Diagnosis and Treatment.
Kashtan CE
Am J Kidney Dis; 2021 Feb; 77(2):272-279. PubMed ID: 32712016
[TBL] [Abstract][Full Text] [Related]
30. Epidermal basement membrane alpha 5(IV) expression in females with Alport syndrome and severity of renal disease.
Massella L; Onetti Muda A; Faraggiana T; Bette C; Renieri A; Rizzoni G
Kidney Int; 2003 Nov; 64(5):1787-91. PubMed ID: 14531812
[TBL] [Abstract][Full Text] [Related]
31. Alport syndrome. Molecular genetic aspects.
Hertz JM
Dan Med Bull; 2009 Aug; 56(3):105-52. PubMed ID: 19728970
[TBL] [Abstract][Full Text] [Related]
32. Spectrum of collagen type IV nephropathies: from thin basement membrane nephropathy to Alport syndrome.
Vizjak A; Ferluga D
Srp Arh Celok Lek; 2008 Dec; 136 Suppl 4():323-6. PubMed ID: 20804103
[TBL] [Abstract][Full Text] [Related]
33. X-linked Alport syndrome associated with a synonymous p.Gly292Gly mutation alters the splicing donor site of the type IV collagen alpha chain 5 gene.
Fu XJ; Nozu K; Eguchi A; Nozu Y; Morisada N; Shono A; Taniguchi-Ikeda M; Shima Y; Nakanishi K; Vorechovsky I; Iijima K
Clin Exp Nephrol; 2016 Oct; 20(5):699-702. PubMed ID: 26581810
[TBL] [Abstract][Full Text] [Related]
34. Autosomal recessive Alport syndrome: an in-depth clinical and molecular analysis of five families.
Longo I; Scala E; Mari F; Caselli R; Pescucci C; Mencarelli MA; Speciale C; Giani M; Bresin E; Caringella DA; Borochowitz ZU; Siriwardena K; Winship I; Renieri A; Meloni I
Nephrol Dial Transplant; 2006 Mar; 21(3):665-71. PubMed ID: 16338941
[TBL] [Abstract][Full Text] [Related]
35. Comparison of alpha5(IV) collagen chain expression in skin with disease severity in women with X-linked Alport syndrome.
Nakanishi K; Iijima K; Kuroda N; Inoue Y; Sado Y; Nakamura H; Yoshikawa N
J Am Soc Nephrol; 1998 Aug; 9(8):1433-40. PubMed ID: 9697665
[TBL] [Abstract][Full Text] [Related]
36. A novel model of autosomal dominant Alport syndrome in Dalmatian dogs.
Hood JC; Huxtable C; Naito I; Smith C; Sinclair R; Savige J
Nephrol Dial Transplant; 2002 Dec; 17(12):2094-8. PubMed ID: 12454218
[TBL] [Abstract][Full Text] [Related]
37. Alport syndrome: a unified classification of genetic disorders of collagen IV α345: a position paper of the Alport Syndrome Classification Working Group.
Kashtan CE; Ding J; Garosi G; Heidet L; Massella L; Nakanishi K; Nozu K; Renieri A; Rheault M; Wang F; Gross O
Kidney Int; 2018 May; 93(5):1045-1051. PubMed ID: 29551517
[TBL] [Abstract][Full Text] [Related]
38. Collagen COL4A3 knockout: a mouse model for autosomal Alport syndrome.
Cosgrove D; Meehan DT; Grunkemeyer JA; Kornak JM; Sayers R; Hunter WJ; Samuelson GC
Genes Dev; 1996 Dec; 10(23):2981-92. PubMed ID: 8956999
[TBL] [Abstract][Full Text] [Related]
39. Distribution of alpha-chains of type IV collagen in glomerular basement membranes with ultrastructural alterations suggestive of Alport syndrome.
Barsotti P; Muda AO; Mazzucco G; Massella L; Basolo B; De Marchi M; Rizzoni G; Monga G; Faraggiana T
Nephrol Dial Transplant; 2001 May; 16(5):945-52. PubMed ID: 11328899
[TBL] [Abstract][Full Text] [Related]
40. Quantitative analysis of glomerular type IV collagen alpha3-5 chain expression in children with thin basement membrane disease.
Ueda T; Nakajima M; Akazawa H; Maruhashi Y; Shimoyama H; Sakagami Y; Takagawa K; Kamitsuji H; Naito I; Sado Y; Yoshioka A
Nephron; 2002 Oct; 92(2):271-8. PubMed ID: 12218303
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
